丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06872 丹诺医药-B

交易中 11-02 15:01:46

66.450

-3.750

-5.34%

最高70.150	最低65.050	成交量3.86万
今开65.050	昨收70.200	日振幅7.27%
总市值34.77亿	流通市值34.77亿	总股本5,232万
成交额255.86万	换手率0.07%	流通股本5,232万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06872","market":"HK","secType":"STK","nameCN":"丹诺医药-B","latestPrice":66.45,"timestamp":1793602672812,"preClose":70.2,"halted":0,"volume":38550,"delay":0,"changeRate":-0.053418803418803416,"floatShares":52317800,"shares":52317800,"eps":-3.845134,"marketStatus":"交易中","change":-3.75,"latestTime":"11-02 15:01:46","open":65.05,"high":70.15,"low":65.05,"amount":2558585,"amplitude":0.07265,"askPrice":66.5,"askSize":350,"bidPrice":65.7,"bidSize":250,"shortable":0,"etf":0,"ttmEps":-3.065,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793607000000},"marketStatusCode":2,"adr":0,"listingDate":1779379200000,"exchange":"SEHK","adjPreClose":70.2,"openAndCloseTimeList":[[1793583000000,1793592000000],[1793595600000,1793606400000]],"volumeRatio":0.33054,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06872","defaultTab":"news","newsList":[{"id":"2679686572","title":"丹诺医药-B(06872)：利福喹酮(TNP-2092)优先开发关节腔内注射给药治疗人工关节感染适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2679686572","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679686572?lang=zh_cn&edition=full","pubTime":"2026-10-30 12:18","pubTimestamp":1793333924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B 发布公告，经综合考虑在研新药候选物利福喹酮 已有的临床数据、未被满足临床需求、竞争格局及商业潜力，本公司已选定通过关节腔内注射给药治疗人工关节感染作为利福喹酮的核心优先开发适应症。作为本集团核心管线，利福喹酮拥有多适应症应用前景。利福喹酮通过关节腔内注射给药治疗PJI，替代手术的IIa期概念验证临床试验取得积极结果，多中心IIb 期临床试验亦已完成首例患者入组。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154431111","title":"丹诺医药-B（06872）将利福喹酮确定为优先开发关节腔内注射治疗人工关节感染核心适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1154431111","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154431111?lang=zh_cn&edition=full","pubTime":"2026-10-30 12:11","pubTimestamp":1793333484,"startTime":"0","endTime":"0","summary":"10月30日，丹诺医药（苏州）股份有限公司发布自愿公告，宣布已将在研新药候选物利福喹酮的核心优先开发方向确立为“关节腔内注射治疗人工关节感染”。公司称，此决定系综合考量已有临床数据、未被满足的医疗需求、竞争格局及商业潜力后作出。公司提醒投资者，药物研发存在不确定性，利福喹酮最终能否成功上市尚待进一步验证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678177715","title":"丹诺医药-B(06872)10月27日斥资约105.32万港元回购约1.12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678177715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678177715?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:27","pubTimestamp":1793104063,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B(06872)发布公告，于2026年10月27日该公司斥资约105.32万港元回购约1.12万股，回购价格为每股83.55至108港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166827484","title":"丹诺医药-B回购11,150股股份，总额约105.32万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166827484","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166827484?lang=zh_cn&edition=full","pubTime":"2026-10-27 20:26","pubTimestamp":1793103968,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年10月27日发布公告，披露在香港联交所场内回购股份的情况。本次回购股份数量为11,150股，占此前已发行股本52,328,926股的约0.021308%，每股价格介乎83.55港元至108港元，累计支付约105.32万港元。根据公告，此次回购于2026年10月23日获公司批准，可回购股份的授权总量为5,232,892股，目前尚余可回购额度为5,221,742股。公司确认，本次交易已遵守香港联交所证券上市规则及相关法律法规，并由董事会正式授权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"丹诺医药-B回购11,150股股份，总额约105.32万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678549147","title":"港股异动 | 丹诺医药-B(06872.HK)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2678549147","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678549147?lang=zh_cn&edition=full","pubTime":"2026-10-27 13:51","pubTimestamp":1793080298,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678147542","title":"港股异动 | 丹诺医药-B(06872)午后飙升16% TNP-2092治疗人工关节感染IIb期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2678147542","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678147542?lang=zh_cn&edition=full","pubTime":"2026-10-27 13:51","pubTimestamp":1793080298,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，丹诺医药-B午后飙升16%。截至发稿，涨4.71%，报97.8港元，成交额2392.77万港元。消息面上，丹诺医药在研新药候选物利福喹酮通过关节腔内注射给药治疗人工关节感染的多中心IIb期临床试验已完成首例患者入组。值得注意的是，丹诺医药公告，公司董事会已获授予购回公司股份的一般性授权，可购回的股份最高数目不超过523.29万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","BK1161","BK4585","VXUS","BK4588","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678659861","title":"丹诺医药-B(06872)拟回购不超过5000万元的H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678659861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678659861?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:03","pubTimestamp":1793005427,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B(06872)公布，鉴于目前H股的市场价格未能充分反映公司的内在价值及业务发展前景，董事会拟根据购回授权行使其权力。经董事会批准，公司将根据市场状况不时于公开市场购回H股，购回总金额不超过人民币5000万元。公司将以自有资金拨付H股购回计划所需资金。董事会相信，在目前市场情况下进行H股购回将表明公司对其自身业务展望及前景的信心，最终将使公司受益，并为股东创造价值。实施H股购回计划将不会对公司的财务状况或其日常业务过程造成重大不利影响。因此，董事会认为实施H股购回计划符合公司及股东的整体利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133573195","title":"丹诺医药-B(06872)第二次临时股东会通过H股激励计划、回购授权及章程修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1133573195","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133573195?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:40","pubTimestamp":1792755635,"startTime":"0","endTime":"0","summary":"丹諾醫藥（蘇州）股份有限公司于2026年10月23日召开2026年第二次临时股东会。会议以投票方式表决全部议案，出席及授权代表共计30,384,754股有表决权股份，占公司已发行52,328,926股H股的58.06%。会议由董事会主席马振坤博士主持。因赞成票超过三分之二，该议案获通过。据公告披露，会议无任何股东须根据香港联交所上市规则第13.40条放弃表决或投票，也无股东提前表示反对或弃权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677918134","title":"丹诺医药-B(06872)：利福喹酮(TNP-2092)通过关节腔内注射给药治疗人工关节感染的多中心IIb期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2677918134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677918134?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:21","pubTimestamp":1792714896,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B 发布公告，公司在研新药候选物利福喹酮 通过关节腔内注射给药治疗人工关节感染的多中心IIb期临床试验已完成首例患者入组。该试验旨在进一步评估利福喹酮在不进行清创或翻修手术的情况下治疗PJI的有效性、安全性和药代动力学特征，标志着这一潜在颠覆性新药产品的临床开发进入关键阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBQ","06872","PSYK","MDTX","IBBJ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189239594","title":"丹诺医药-B：TNP-2092关节腔内注射治疗人工关节感染IIb期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1189239594","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189239594?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:06","pubTimestamp":1792713964,"startTime":"0","endTime":"0","summary":"2026年10月23日，丹諾醫藥（蘇州）股份有限公司披露，其在研新药候选物利福喹酮用于关节腔内注射治疗人工关节感染的多中心IIb期临床试验已完成首例患者入组。该试验计划在随机、对照、开放标签设计下，入组40例成年受试者，主要研究终点为开始研究治疗后6个月的有效性。研究将评估在无需清创或翻修手术的情况下，TNP-2092关节腔内注射联合系统抗菌药物的治疗有效性、安全性及药代动力学特征。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115758863","title":"丹诺医药-B更新9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1115758863","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115758863?lang=zh_cn&edition=full","pubTime":"2026-10-02 20:55","pubTimestamp":1790945737,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司（丹诺医药-B，股票代码：06872）于2026年10月2日发布了截至2026年9月30日的股份变动月报表。报告显示，公司当月股本结构保持稳定。\n根据公告，丹诺医药-B报告期内普通股（H 股）已发行股份总数仍为52,328,926股，注册股本人民币52,328,926元，较上月未发生变化。同时，本月内无新增股份发行、购回、注销或库藏股，相应的股份数量保持不变。公司声明已符合香港联交所相关上市规则的最低25%公众持股量要求。\n本次月报由公司董事会主席、执行董事、首席执行官兼总经理马振坤签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102594002","title":"丹诺医药-B授予董事会回购授权，拟回购已发行H股10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1102594002","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102594002?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:38","pubTimestamp":1790930331,"startTime":"0","endTime":"0","summary":"丹诺医药-B日前在香港联合交易所有限公司披露公告，计划于2026年10月23日召开2026年第二次临时股东大会，审议并授权董事会在不超过已发行H股股本10%的范围内进行股份购回。根据公告，截至最后实际可行日期2026年9月30日，公司已发行H股数量约为52,328,926股，如购回计划获批，最高可回购约5,232,892股。公司提醒，股东可于2026年10月16日下午4时30分前办理股份过户手续，2026年10月20日至10月23日期间暂不受理H股股份过户登记。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丹诺医药-B授予董事会回购授权，拟回购已发行H股10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167890416","title":"丹诺医药-B（06872）将于10月23日召开第二次临时股东大会 审议H股激励计划及回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1167890416","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167890416?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:38","pubTimestamp":1790930317,"startTime":"0","endTime":"0","summary":"丹诺医药-B10月5日公告，公司拟于2026年10月23日14:00在江苏省苏州工业园区星湖街218号生物医药产业园B7楼701室召开2026年第二次临时股东大会。为确定出席资格，H股过户登记将于10月20日至23日暂停，10月23日名列股东名册者可参会。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144520083","title":"丹诺医药-B 2026年上半年营收0百万元，经调整净亏损64.25百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144520083","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144520083?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:57","pubTimestamp":1790240270,"startTime":"0","endTime":"0","summary":"2026年上半年，丹诺医药-B并未从产品销售获得收入，整体营收维持在0百万元。经调整净亏损为64.25百万元，较上一年同期的78.17百万元下降约17.80%。研发投入由上年同期的26.32百万元增长至31.32百万元，同比增长约19.03%。管理费用则从18.61百万元提升至32.01百万元，同比增幅约72.09%。经营现金流方面，上半年经营性现金流出59.23百万元，较上年同期的39.99百万元有所扩大，主要与公司在研发活动和业务布局方面的持续投入相关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"丹诺医药-B 2026年上半年营收0百万元，经调整净亏损64.25百万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114700","title":"港股异动 | 丹诺医药-B(06872.HK)盘中涨超6% TNP-2092 2a期概念验证临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669114700?lang=zh_cn&edition=full","pubTime":"2026-09-22 15:49","pubTimestamp":1790063396,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187398373","title":"丹诺医药-B（06872）拟设立2026年H股股份奖励计划并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1187398373","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187398373?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:06","pubTimestamp":1789999601,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司9月21日公告称，公司董事会已决议：制订2026年H股股份奖励计划；修订《丹诺医药（苏州）股份有限公司章程》。上述事项尚需提交公司即将召开的临时股东会审议批准后方可生效。公司表示，将在适当时候刊发载有上述议案详情及临时股东会通知的通函。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669691951","title":"丹诺医药-B(06872.HK)：制订2026年H股股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2669691951","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669691951?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:01","pubTimestamp":1789999265,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666335517","title":"华福证券：PJI无手术时代临近 创新疗法需求迫切","url":"https://stock-news.laohu8.com/highlight/detail?id=2666335517","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666335517?lang=zh_cn&edition=full","pubTime":"2026-09-11 09:37","pubTimestamp":1789090634,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华福证券发布研报称，全球人工关节感染疾病负担沉重且持续扩容，当前标准手术治疗方案2年累计再感染率仍超10%，临床对突破生物膜屏障的创新疗法需求迫切。当前抗菌肽，噬菌体，单抗均定位于手术清创后联合使用减少再感染风险，进一步避免二次手术。而关节腔注射给药的关节滑液浓度会更高，2a数据显示，在小样本早期/急性PJI中，无手术情况下，利福喹酮12个月中的治疗成功率为100%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872","161027","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120373262","title":"丹诺医药-B公布Rifaquizinone（TNP-2092）IIa期概念验证积极数据，为假体周围关节感染首款非手术候选疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1120373262","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120373262?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:32","pubTimestamp":1789039961,"startTime":"0","endTime":"0","summary":"丹诺医药-B今日宣布，其核心在研药物Rifaquizinone在IIa期概念验证研究中取得积极结果。这一候选药物被视为针对假体周围关节感染的首个非手术疗法候选方案。在临床研究中，Rifaquizinone展现出令人鼓舞的安全性与疗效信号。丹诺医药进一步指出，IIa期研究的积极结果不仅验证了药物的早期临床潜力，也为其快速推进至后期开发阶段提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665340203","title":"港股异动 | 丹诺医药-B(06872)涨超7% 日前获纳入港股通名单 利福喹酮IIa期概念验证数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2665340203","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665340203?lang=zh_cn&edition=full","pubTime":"2026-09-08 15:04","pubTimestamp":1788851053,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，丹诺医药-B涨超7%，该股昨日曾冲高涨超15%，随后跳水收跌逾8%。截至发稿，涨7.45%，报165.8港元，成交额2741.28万港元。消息面上，9月7日起，丹诺医药正式获纳入港股通名单。公司表示，此次获纳入港股通，是资本市场对本公司投资价值、市值规模及流动性的全面认可。丹诺医药专注于细菌感染及细菌代谢相关疾病领域。9月7日，丹诺医药公布，利福喹酮治疗人工关节感染的IIa期概念验证临床取得积极结果，多中心IIb期试验已启动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","VXUS","FLHK","06872","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tennortherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.2668},{"period":"1month","weight":-0.3912},{"period":"3month","weight":-0.5621},{"period":"6month","weight":-0.0727},{"period":"ytd","weight":-0.0727}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.1137},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丹诺医药（苏州）股份有限公司（原名：丹诺医药（苏州）有限公司）是一家主要从事发现、开发及商业化差异化的创新药产品的中国公司。该公司的产品主要包括用于治疗幽门螺杆菌的新分子实体候选药物利福特尼唑（TNP-2198）、用于治疗植入体相关细菌感染的三靶点抗菌候选药物利福喹酮（TNP-2092）注射剂、用于治疗肠道菌群代谢相关疾病的多靶点抗菌候选药物TNP-2092口服制剂、化学系列小分子TNBi-1、多靶点偶联药物系列TNBi-2以及化学系列双功能小分子TNBm-1。该公司专注于细菌感染和代谢相关疾病领域。","exchange":"SEHK","name":"丹诺医药-B","nameEN":"TENNOR THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丹诺医药-B,06872,丹诺医药-B股票,丹诺医药-B股票老虎,丹诺医药-B股票老虎国际,丹诺医药-B行情,丹诺医药-B股票行情,丹诺医药-B股价,丹诺医药-B股市,丹诺医药-B股票价格,丹诺医药-B股票交易,丹诺医药-B股票购买,丹诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}